Keros Therapeutics
KROS
132 hedge funds and large institutions have $199M invested in Keros Therapeutics in 2026 Q2 according to their latest regulatory filings, with 15 funds opening new positions, 47 increasing their positions, 50 reducing their positions, and 30 closing their positions.
0.56% less ownership
Funds ownership: 94.31% → 93.75% (-0.56%)
3% less capital invested
Capital invested by funds: $206M → $199M (-$6.99M)
6% less repeat investments, than reductions
Existing positions increased: 47 | Existing positions reduced: 50
13% less funds holding
Funds holding: 151 → 132 (-19)
50% less first-time investments, than exits
New positions opened: 15 | Existing positions closed: 30
73% less call options, than puts
Call options by funds: $42K | Put options by funds: $154K
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
AQR Capital Management
Greenwich,
Connecticut
|
+$6.25M |
| 2 |
Mackenzie Financial
Toronto Ontario,
Ontario, Canada
|
+$5.3M |
| 3 |
BlackRock
New York
|
+$4.26M |
| 4 |
ACM
ADAR1 Capital Management
Austin,
Texas
|
+$1.67M |
| 5 |
Dimensional Fund Advisors
Austin,
Texas
|
+$1.55M |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
Arrowstreet Capital
Boston,
Massachusetts
|
-$3.98M |
| 2 |
D.E. Shaw & Co
New York
|
-$2.7M |
| 3 |
Geode Capital Management
Boston,
Massachusetts
|
-$1.9M |
| 4 |
Connor, Clark & Lunn Investment Management (CC&L)
Vancouver,
British Columbia, Canada
|
-$1.45M |
| 5 |
Two Sigma Investments
New York
|
-$1.31M |
KROS Hedge Fund Activity: Q2 2026 in Review
132 of the 8,305 institutional investors tracked by Wall St. Rank reported a position in Keros Therapeutics (KROS) for Q2 2026, worth a combined $199M — down 3.4% from $206M a quarter earlier.
Sellers outnumbered buyers: 30 funds closed out of KROS and 15 opened new positions — a net loss of 15 holders — while 50 trimmed existing stakes and 47 added.
The largest buyer was AQR Capital Management, adding an estimated $6.25M. The largest seller was Arrowstreet Capital, cutting an estimated $3.98M.
- 132 institutional investors held Keros Therapeutics (KROS) as of Q2 2026, down from 151 in Q1 2026.
- Funds reported $199M of Keros Therapeutics stock for Q2 2026, down 3.4% quarter-over-quarter.
- 15 funds opened new Keros Therapeutics positions in Q2 2026 and 30 closed out, a net change of -15 holders.
- The largest Keros Therapeutics buyer in Q2 2026 was AQR Capital Management, an estimated $6.25M added.
- The largest Keros Therapeutics seller in Q2 2026 was Arrowstreet Capital, an estimated $3.98M sold.
Based on aggregated 13F filings for Q2 2026.